Nigeria has approved the R21 malaria vaccine, making it the second country to do so

Posted by

The R21 malaria vaccine made by the Serum Institute of India got permission from the National Agency for Food and Drug Administration and Control.

Nigeria now agrees to use the new malaria vaccine made by the University of Oxford, just like Ghana did already.

On Monday April 17th, Prof. spoke at a meeting in Abuja. Mojisola Adeyeye, who is the boss of NAFDAC, told everyone about it.

Prof Adeyeye said that the vaccine can help stop children who are 5 months to 36 months old from getting very sick with malaria.

She said that the country will receive 100,000 doses of the vaccine soon for free. After that, they will begin working with the National Primary Health Care Development Agency to make further plans.

Adeyeye spoke.
NAFDAC gave permission for a new malaria vaccine called R21. It was made by a company in India called Serum Institute of India Pvt. Company.

Fidson Healthcare Ltd is in charge of getting permission from the agency to sell drugs and related products according to the 2021 rules.

The R21 Malaria vaccine is a shot with protein that helps protect against Malaria. It is a clear liquid without any germs. A small amount of liquid medicine ready for injection has two parts: R21 Malaria antigen and Matrix-M1 adjuvant. It is in a vial and is 0.5ml.

The vaccine helps keep children aged 5 months to 36 months from getting sick with malaria. The vaccine needs to be kept at a temperature between 2 and 8 degrees Celsius.

She said that people who don’t work for the vaccine company looked at the document twice.

READ ALSO:  Rich businessman Otedola bought 5.52% of Transcorp

The NAFDAC’s Vaccine Advisory Committee examined the report following specific rules set by the World Health Organization, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human use, and the European Medicines Agency. They also looked at the vaccine’s scientific accuracy and how it relates to malaria in Nigeria. They made sure that the research and production of the vaccine followed the best possible procedures.

Adeyeye said that a group called NEVAC looked at everything carefully and talked about it together. They asked questions and gave suggestions about each part.

In simple words: The assessment was good and followed all the rules. The report was sent to the boss.

The group in charge of checking NAFDAC’s work always uses the same rules as other countries and the same way of working together separately, then talking a lot to make sure everything is good. The Committee said the assessment was good and gave it to the boss.

She said that the R21 malaria vaccine information met the highest standards that were used as a comparison.

She said a group of experts reviewed the information on the R21 Malaria vaccine and found it to be strong and met the standards for effectiveness, safety, and quality.

The vaccine is good because its benefits are better than its risks, and it’s safe to use as recommended by the manufacturer.

A group of people who review things said it is very important to have a good malaria shot that can protect 75% of people. This is really needed in Nigeria, where lots of people get malaria.

READ ALSO:  Osun establishes a national food safety policy

The Joint Review Committee suggested doing more tests and studies to make sure a malaria medication works well in Nigeria because malaria is different in different parts of the country.

The people in charge wanted to look at information about malaria in the 25% of people that weren’t protected. They wanted to figure out why they weren’t protected so they can do more research on it.

She said that the R21 Malaria Vaccine was approved for now and will be used according to the WHO’s Malaria Vaccine Implementation Guideline.

Leave a Reply